Kenny Walter

In data presented during the annual ACG meeting, investigators show vedolizumab can be safe and effective for treating pediatric patients with IBD who have failed anti-TNF therapy.

In a new poster presented at the annual ACG meeting in San Antonio, researchers compare morbidity and mortality for ulcerative colitis patients with or without C. diff or CMV infections.

The rapid-acting insulin will now be used in infusion pumps to treat adults with Type 1 or Type 2 diabetes.

The FDA is allowing Rocket Pharmaceuticals to conduct a global phase I study testing a new treatment approach for Pyruvate Kinase Deficiency.

The newly approved drug is a combination of 3 drugs that target the most common cystic fibrosis mutation.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.

The FDA set a 2020 PDUFA action date for FMX103, a topical foam to treat papulopustular rosacea.

Investigators discover vedolizumab induces endoscopic remission in 33% of Crohn’s disease patients and histologic remission in 66% of patients after 52 weeks.

With ARBs linked to a higher risk of suicide, investigators suggest treating diseases like hypertension, chronic kidney disease, heart failure, and diabetes with ACEIs instead.

In a phase 3b study, 75% of patients using HTX-011 were discharged without opioids following a total knee arthroplasty.

The results of a new survey regarding quality of care for end stage renal disease patients raise questions about how to improve the quality of end-of-life care.

The new transdermal patch offers a new delivery option for a well-established schizophrenia treatment.

A pair of surveys show the majority of patients suffering from Parkinson disease would be willing to take CBD to manage psychosis symptoms if it is proven safe and effective.

While depression does not impact functional recovery much following discharge, both dementia and delirium could affect a geriatric patient’s functional status.

Hepatitis C virus infections are strongly linked to type 2 diabetes, according to new research.

Investigators suggest an upgrade to the existing categorical frameworks for diagnosing mental illnesses, such as obsessive-compulsive disorder and generalized anxiety disorder.

The geko device is designed to increase blood circulation and edema reduction to prevent venous thrombosis in non-surgical patients.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

The new implanted drug will help treat adults suffering from erythropoietic protoporphyria with a history of photoxic reactions.

Investigators take a deeper look into the association between burnout and quality of care.

In an extensive analysis, investigators link antipsychotic initiators with more days in the hospital for Alzheimer disease patients.

Higmark Interactive will now be able to market their full suite of EQ software modules.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

AKLIEF Cream, a topical cream to treat acne on the face and trunk, is expected to be available in the US in November.

RenalGuard Solutions officials are claiming success in the REMEDIAL III trial for a new product that creates high urine output to prevent kidney injuries during interventional procedures.

The Biovitals Analytics Engine is able to read physiology signals to allow doctors to change the trajectory of disease weeks in advance.

In a new meta-analyses, investigators find a lack of evidence showing the links between antidepressants and adverse health risks.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

In a review of chronic kidney disease, investigators suggest a variety of screening and risk reduction measures.

Investigators deem phase 2 study using pimavanserin to treat major depressive disorder a success.